Glucotrack Inc Announces Peer-Reviewed Study Supporting Long-Life Sensor Design For Implantable Continuous Blood Glucose Monitoring Technology Apr 23
High number of new and inexperienced directors Apr 04
New major risk - Financial position Apr 01
Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 Milestones Mar 27
New major risk - Share price stability Feb 01
GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.999997 million. Dec 30
New major risk - Financial position Nov 16
Glucotrack, Inc. Appoints Usman Latif to its Clinical Advisory Team Oct 30
GlucoTrack, Inc. announced that it has received $3 million in funding Sep 13
GlucoTrack, Inc. announced that it expects to receive $20 million in funding from Sixth Borough Capital Management, LP. Sep 12
Glucotrack, Inc. Appoints David S. Hirsh, MD as Medical Director, Cardiology Aug 06
Glucotrack, Inc. and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor At American Diabetes Association's 85Th Scientific Sessions Jun 25
Glucotrack, Inc. Approves the Election of Victoria Carr-Brendel as Director May 24
New major risk - Financial position May 15
Glucotrack, Inc. Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor May 14
GlucoTrack, Inc., Annual General Meeting, May 22, 2025 Apr 22
Nasdaq Determines to Delist GlucoTrack Securities Due to Non-Compliance with Bid Price Rule Apr 05
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member Feb 26
GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.033748 million. Feb 05
Glucotrack, Inc. Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor Feb 04
GlucoTrack Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price Requirement Jan 31
GlucoTrack, Inc. Announces Chief Financial Officer Changes Jan 30
GlucoTrack, Inc. Receives Nasdaq Non-Compliance Letter Regarding Bid Price Rule Jan 01
GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $8.23 million. Dec 18
GlucoTrack, Inc. Announces Start of Enrollment for Human Clinical Study of Continuous Blood Glucose Monitor Dec 03
GlucoTrack, Inc. has completed a Follow-on Equity Offering in the amount of $9.995237 million. Nov 15
Glucotrack, Inc. Appoints John Ballantyne to Its Board of Directors Sep 03
GlucoTrack, Inc. announced that it has received $0.1 million in funding Jul 02
Glucotrack Announces the Appointment of Andy Balo to Board of Directors Jun 20
Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor Jun 15
Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor Jun 06
GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance Period May 25
Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study May 18
Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Requirement May 17
GlucoTrack, Inc. announced that it has received $0.5 million in funding Apr 23
GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring Apr 18
Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor Apr 03
GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024 Apr 02
Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors Feb 13
GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor Jan 03
GlucoTrack, Inc. Announces Executive Changes Oct 13
Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee Sep 01
Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor Jul 26
GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2) Jun 03
Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain Compliance Feb 14
Glucotrack to Begin Research & Development of Novel Continuous Glucose Monitoring System Oct 11
GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor Jun 23
Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022 Mar 29
Integrity Applications, Inc. announced delayed 10-Q filing May 18
Integrity Applications, Inc. announced delayed annual 10-K filing Apr 02
Integrity Applications, Inc. Announces Executive Changes Feb 10
Integrity Applications Appoints Paul V. Goode to Board of Directors Dec 19
Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020 Nov 06
Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020 Oct 10 